Comments
Pharma major Dr Reddy’s Laboratories Ltd. has received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug Molnupiravir capsules 200mg for treatment of adult patients with Covid-19.
The drug has been authorised to be used for Covid-19 patients who have high risk of disease progression including hospitalisation or death.
Earlier this year, Dr. Reddy’s entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).
Also read: Torrent, Cipla, Sun announce branded versions of molnupiravir in India
In a first-of-its-kind collaboration in the Indian pharmaceutical industry, a Dr. Reddy’s-led consortium of pharma companies collaborated to jointly sponsor, supervise and monitor the phase III clinical trial in India, and presented its findings to the Subject Expert Committee (SEC).
Hyderabad-based Dr Reddy’s will soon launch its Molnupiravir capsules 200mg under the brand name Molflu across India.
“The approval to launch Molnupiravir is an important development not only as a treatment option, but also for the collaborative manner in which Indian pharma companies came together,” GV Prasad, Co-Chairman and Managing Director, Dr Reddy’s, said in a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.